InsiderTrades.com logo
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
From Darwin   |   Ad
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
👉 Click here to access your FREE report now!
Esteban Lopez net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Esteban Lopez Biography and Net Worth

Director of Axonics
Dr. López has served as a member of the Board since July 2021. Since January 2021, he has served on the Board of Directors of Addus HomeCare Corporation (NASDAQ: ADUS), a publicly traded provider of home care services, and is the founder and CEO of Hopscotch Health, a clinical practice focused on children's urgent care needs. From September 2020 to March 2023, he served as the Americas healthcare and life sciences Market Lead at Google Cloud with multinational executive responsibility for strategy and solutions development. From March 2013 to December 2019, he worked at Health Care Service Corporation (HCSC) in several executive roles, most recently as Chief Medical Officer for Clinical Strategy and Innovation. HCSC is the fourth largest health insurer in the U.S. Dr. López received a B.A. in biology from the University of California, Santa Cruz, his medical degree from Michigan State University College of Human Medicine, and his MBA from the University of Texas at Dallas. Dr. López is dual board certified in both internal medicine and pediatrics and continues to practice medicine in his free time at Hopscotch Health.

What is Esteban Lopez's net worth?

The estimated net worth of Esteban Lopez is at least $238,918.68 as of September 10th, 2024. Dr. Lopez owns 3,366 shares of Axonics stock worth more than $238,919 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Lopez may own. Learn More about Esteban Lopez's net worth.

How do I contact Esteban Lopez?

The corporate mailing address for Dr. Lopez and other Axonics executives is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. Axonics can also be reached via phone at (949) 396-6322 and via email at [email protected]. Learn More on Esteban Lopez's contact information.

Has Esteban Lopez been buying or selling shares of Axonics?

Esteban Lopez has not been actively trading shares of Axonics in the last ninety days. Most recently, Esteban Lopez sold 2,000 shares of the business's stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $67.42, for a transaction totalling $134,840.00. Following the completion of the sale, the director now directly owns 3,600 shares of the company's stock, valued at $242,712. Learn More on Esteban Lopez's trading history.

Who are Axonics' active insiders?

Axonics' insider roster includes Juliet Bakker (Director), Raymond Cohen (Co-Founder, Chief Executive Officer and Director), Danny Dearen (Insider), Alfred Ford, Jr. (Insider), Kari Keese (CFO), Jane Kiernan (Director), Esteban Lopez (Director), Robert Mcnamara (Director), Karen Noblett (Insider), Rinda Sama (COO), and John Woock (CMO). Learn More on Axonics' active insiders.

Are insiders buying or selling shares of Axonics?

During the last year, insiders at the sold shares 8 times. They sold a total of 92,797 shares worth more than $6,275,226.67. The most recent insider tranaction occured on October, 2nd when CFO Kari Leigh Keese sold 2,961 shares worth more than $205,523.01. Insiders at Axonics own 1.9% of the company. Learn More about insider trades at Axonics.

Information on this page was last updated on 10/2/2024.

Esteban Lopez Insider Trading History at Axonics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2022Sell2,000$67.42$134,840.003,600View SEC Filing Icon  
See Full Table

Esteban Lopez Buying and Selling Activity at Axonics

This chart shows Esteban Lopez's buying and selling at Axonics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Axonics Company Overview

Axonics logo
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Read More

Today's Range

Now: $70.98
Low: $70.98
High: $70.98

50 Day Range

MA: $70.00
Low: $68.70
High: $70.98

2 Week Range

Now: $70.98
Low: $55.09
High: $71.05

Volume

N/A

Average Volume

571,295 shs

Market Capitalization

$3.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
From Darwin   |   Ad
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
👉 Click here to access your FREE report now!